Abstract:dThe reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) and Etest, was prospectively assessed for 10 methicillin-resistant Staphylococcus aureus (MRSA) isolates from the blood samples from patients on vancomycin therapy. The isolates were tested at the time of isolation from blood and following 5, 10, and 20 subcultures and at 1, 3, 6, and 12 months of storage at ؊70°C. The MICs were determined by Etest and BMD using two different manufacturers (BBL and Difco) of cation-ad… Show more
“…For example, colistin MICs for P. aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii have been shown to decrease from a resistant/non-wild-type phenotype to a susceptible/wild-type phenotype after frozen storage (8). Similarly, vancomycin MICs for Staphylococcus aureus have been shown to decrease after 1 year of frozen storage (9). Details to be included in Materials and Methods for the evaluation, regarding how the cAST was performed, are outlined in Table 2.…”
Effective evaluations of antimicrobial susceptibility tests (ASTs) require robust study design. The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing has recognized that many published studies reporting the performance of commercial ASTs (cASTs) suffer from major design and/or analysis flaws, rendering the results difficult or impossible to interpret. This minireview outlines the current consensus of the Methods Development and Standardization Working Group of the CLSI Subcommittee on Antimicrobial Susceptibility Testing regarding best practices for systematic evaluation of the performance of an AST, including the analysis and presentation of essential data intended for publication.
“…For example, colistin MICs for P. aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii have been shown to decrease from a resistant/non-wild-type phenotype to a susceptible/wild-type phenotype after frozen storage (8). Similarly, vancomycin MICs for Staphylococcus aureus have been shown to decrease after 1 year of frozen storage (9). Details to be included in Materials and Methods for the evaluation, regarding how the cAST was performed, are outlined in Table 2.…”
Effective evaluations of antimicrobial susceptibility tests (ASTs) require robust study design. The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing has recognized that many published studies reporting the performance of commercial ASTs (cASTs) suffer from major design and/or analysis flaws, rendering the results difficult or impossible to interpret. This minireview outlines the current consensus of the Methods Development and Standardization Working Group of the CLSI Subcommittee on Antimicrobial Susceptibility Testing regarding best practices for systematic evaluation of the performance of an AST, including the analysis and presentation of essential data intended for publication.
“…On
one hand, to deepen this question, we performed the antibacterial testing of the
composite pastes in vitro . On the other hand, with the release
totaling ~ 2 % of the total drug content in the first 24 h, equaling 2 mg/g
of the paste, it would take only 1 g/dm 3 of the paste to reach the
uppermost end of the MIC for vancomycin against methicillin-resistant S.
aureus (2 μg/ml) 49 in this period of time. Such an absence of the burst release
indicates that the antibiotic is almost completely confined to the interior of the
hardened paste and that the degradation of the paste in an aqueous environment will
precondition its antibacterial activity.…”
Bone grafting is one of the commonest surgical procedures, yet all bone
substitutes developed so far suffer from specific weaknesses and the search for
a bone graft material with ideal physical and biological properties is still
ongoing. Calcium phosphate pastes are the most frequently used synthetic bone
grafts, yet they (a) often take an impractically long time to set, (b) release
the drug content too fast, and (c) do not form pores large enough to accommodate
host cells and foster osseointegration. To make up for these deficiencies, we
introduced gelatin and silica to pastes composed of 5–15 nm sized
hydroxyapatite nanoparticles and yielded a bioresorbable composite that is
compact, yet flowing upon injection; that prevents setting at room temperature,
but sets promptly, in minutes, at 37 °C; that displays an increase in
surface porosity following immersion in physiological fluids; that allows for
sustained release of antibiotics; and that sets in a tunable manner and in
clinically relevant time windows: 1–3 minutes at its fastest. Timelapse,
in situ X-ray diffraction analysis demonstrated that the
setting process is accompanied by an increase in crystallinity of the initially
amorphous hydroxyapatite, involving no polymorphic phase transitions in its
course. Setting time can be tuned by controlling the weight content of gelatin
or powder-to-liquid ratio. The release of vancomycin was slow, ~ 8 %
after 2 weeks, and unaffected by the gelatin content. While vancomycin-loaded
pastes were effective in reducing the concentration of all bacterial species
analyzed, the bacteriostatic effects of the antibiotic-free pastes were
pronounced against S. liquefaciens and E. coli. S.
liquefaciens bacilli underwent beading and filamentation during the
treatment, suggesting that the antimicrobial effects are attributable to cell
wall disruption by hydroxyapatite nanoparticles. Vancomycin-loaded pastes
augmented the activity of the antibiotic against P. aeruginosa
and S. liquefaciens, while exhibiting no negative effects
against human mesenchymal stem cells. They were also uptaken three times more
abundantly than pure hydroxyapatite, indicating the theoretical favorability of
their use for intracellular delivery of therapeutics. This selectivity, toxic
for bacteria and harmless for primary stem cells, is promising for application
as bone grafts for osteomyelitis.
“…In MRSA strains with heterogenous resistance, after separation from blood and sub-culture on drug-free, nutrient-rich medium, the lower MICs observed in isolates after sub-culturing of positive blood cultures may reflect a change in the MRSA population being tested. Although a previous study reported no differences in VAN MICs after repeated sub-cultures, that study did not compare sub-cultured MRSA and direct VAN MIC testing [11].…”
Introduction. Empirical vancomycin (VAN) treatment failure for methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia, with significantly higher mortality, has been reported for MRSA strains with reduced VAN susceptibility.Aim. Our goal was to study the effect of sub-culture on VAN minimum inhibitory concentration (MIC) values compared to direct susceptibility of MRSA-positive blood cultures.Methodology. Using 19 MRSA-positive blood cultures and 19 seeded MRSA-positive blood cultures, we compared the VAN MICs from direct susceptibility testing of MRSA-positive blood cultures and MRSA sub-cultured from positive blood cultures.Results. In comparing direct VAN MICs from MRSA-positive blood cultures and standard agar dilution, nearly half of the MICs from agar dilution were lower, with one sample decreasing from 1.5 to 0.75 µg ml−1. Furthermore, in seeded blood cultures, 80 % or more showed lower values from standard agar dilution compared to direct VAN MICs.Conclusion. Our results reveal a trend towards lower MICs after positive blood culture isolates are sub-cultured. Some clinical failures among MRSA infections treated with VAN may result from this phenomenon.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.